Lyra Therapeutics, Inc.
LYRA
$0.0873
$0.00080.93%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -93.44M | -97.61M | -101.39M | -68.88M | -62.68M |
| Total Depreciation and Amortization | 471.00K | 405.00K | 298.00K | 130.00K | 278.00K |
| Total Amortization of Deferred Charges | 140.00K | 140.00K | 140.00K | -- | -- |
| Total Other Non-Cash Items | 29.16M | 27.88M | 27.18M | 4.33M | 3.98M |
| Change in Net Operating Assets | -6.35M | -8.53M | -1.83M | -5.49M | -4.89M |
| Cash from Operations | -70.01M | -77.72M | -75.61M | -69.91M | -63.30M |
| Capital Expenditure | -2.34M | -3.18M | -3.28M | -3.15M | -1.05M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 82.64M | 53.00M | 29.97M | -6.89M | -11.54M |
| Cash from Investing | 80.31M | 49.82M | 26.70M | -10.04M | -12.58M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 8.82M | 28.06M | 28.07M | 78.15M | 69.35M |
| Repurchase of Common Stock | -1.00K | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -290.00K | -612.00K | -1.01M | -3.82M | -3.65M |
| Cash from Financing | 8.53M | 27.45M | 27.06M | 74.33M | 65.69M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 18.83M | -450.00K | -21.86M | -5.62M | -10.20M |